IP Verse

An Anhydrous Pharmaceutical Composition For Maintenance Treatment Of Psoriasis

Patent No. EP4041186 (titled "An Anhydrous Pharmaceutical Composition For Maintenance Treatment Of Psoriasis") was filed by LEO Pharma on Oct 7, 2020. The application was issued on May 22, 2024.

Patent Summary

An anhydrous topical pharmaceutical composition for maintaining psoriasis remission by treating psoriasis patients when they are in remission following an initial course of therapy. The composition contains calcipotriol, betamethasone, petrolatum, and a propellant. The patients apply the composition biweekly when they are in remission to prevent relapses and prolong remission duration compared to not using the composition. The biweekly maintenance treatment reduces relapse rate, time to first relapse, and improves remission duration versus no maintenance therapy.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HGFFeb 24, 2025HGF
GENERICS UKFeb 21, 2025ELKINGTON AND FIFE
DR SCHONFeb 17, 2025DR SCHON

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4041186

LEO PHARMA
Application Number
EP20789063A
Filing Date
Oct 7, 2020
Status
Granted And Under Opposition
Apr 19, 2024
Publication Date
May 22, 2024
External Links
Slate, Register , Google Patents